. Author manuscript; available in PMC: 2021 Mar 22.

Published in final edited form as: J Urol. 2018 Jan 20;199(4):976–982. doi: 10.1016/j.juro.2017.10.048

Table 2.

Paired analysis of biopsy modalities showing upgrade rates from biopsy to final prostatectomy

	No. mpMRI-TRUS Biopsy (%)
Systematic 12-Core Biopsy	No Prostatectomy Upgrade^*	Prostatectomy Upgrade

Final prostatectomy Gleason score:
No upgrade	86 (41.3)	24 (11.5)
Upgrade	59 (28.4)	39 (18.8)
Final prostatectomy risk category:
No upgrade	102 (49.0)	21 (10.1)
Upgrade	57 (27.4)	28 (13.5)

Pathological data from systematic and mpMRI-TRUS fusion biopsies were analyzed for maximum Gleason score and risk category, and compared with corresponding data from prostatectomy on each patient. If prostatectomy Gleason score or risk category was higher than systematic, fusion or combined biopsy Gleason score or risk category, case was deemed upgraded in corresponding biopsy category. Upgrade rates of each biopsy modality were recorded for patients with saturation biopsy and those with nonsaturation fusion biopsy of index tumor.

McNemar test p <0.001.